Comparing Adoption of Breakthrough and “Me-too” Drugs Among Medicare Beneficiaries: a Case Study of Dipeptidyl Peptidase-4 Inhibitors

被引：0
|
作者：
Inmaculada Hernandez
Yuting Zhang
机构：
[1] University of Pittsburgh,Department of Pharmacy and Therapeutics
[2] University of Pittsburgh,Department of Health Policy and Management
来源：
Journal of Pharmaceutical Innovation | 2017年 / 12卷
关键词：
Diffusion of innovation; Prescription drugs; Medicare Part D; Medicare Advantage;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：105 / 109
页数：4
相关论文
共 50 条
  • [21] COSTS FOR DIABETIC PATIENTS RECEIVING DIPEPTIDYL PEPTIDASE-4 (DPP-4) INHIBITORS IN US MEDICARE AND COMMERCIAL INSURANCE PLANS
    Rascati, K. L.
    Worley, K.
    Everhart, D.
    Meah, Y.
    VALUE IN HEALTH, 2015, 18 (07) : A601 - A602
  • [22] Bullous Pemphigoid Associated With Dipeptidyl Peptidase-4 Inhibitors: A Case Report and Review of Current Evidence
    Hadjkacem, Faten
    Frikha, Hamdi
    Boujelben, Khouloud
    Chaari, Chiraz
    Mnif, Emna
    Masmoudi, Abderrahmen
    Boudawara, Tahia
    Turki, Hamida
    Abid, Mohamed
    HOSPITAL PHARMACY, 2023, 58 (04) : 357 - 362
  • [23] Comparative risk of musculoskeletal adverse reactions among new users of dipeptidyl peptidase-4 inhibitors: A retrospective cohort study
    Park, Taehwan
    Bresnahan, Maureen
    Griggs, Scott K.
    Chen, Jiajing
    Cho, Alex H.
    Gousse, Yolene
    Feinglos, Mark
    EXPLORATORY RESEARCH IN CLINICAL AND SOCIAL PHARMACY, 2021, 2
  • [24] Dipeptidyl peptidase-4 inhibitors and the risk of biliary tract diseases among patients with type 2 diabetes
    Shapiro, Samantha B.
    Yin, Hui
    Yu, Oriana H. Y.
    Azoulay, Laurent
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 83 - 84
  • [25] Risk of myocardial infarction in trials with Dipeptidyl Peptidase-4 inhibitors: Is duration of study a real issue?
    Dicembrini, Ilaria
    Mannucci, Edoardo
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2015, 184 : 543 - 544
  • [26] Dipeptidyl peptidase-4 inhibitors and the risk of acute liver injury among patients with type 2 diabetes
    Pradhan, Richeek
    Yin, Hui
    Yu, Oriana Hoi Yun
    Azoulay, Laurent
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 114 - 114
  • [27] Is there an association between dipeptidyl peptidase-4 inhibitors and autoimmune disease? A population-based study
    Khalaf Kridin
    Kyle Amber
    Mogher Khamaisi
    Doron Comaneshter
    Erez Batat
    Arnon D. Cohen
    Immunologic Research, 2018, 66 : 425 - 430
  • [28] Is there an association between dipeptidyl peptidase-4 inhibitors and autoimmune disease? A population-based study
    Kridin, Khalaf
    Amber, Kyle
    Khamaisi, Mogher
    Comaneshter, Doron
    Batat, Erez
    Cohen, Arnon D.
    IMMUNOLOGIC RESEARCH, 2018, 66 (03) : 425 - 430
  • [29] Dynamics of switching, adherence, and persistence of dipeptidyl peptidase-4 inhibitors use: A nationwide cohort study
    Ofori-Asenso, Richard
    Ilomaki, Jenni
    Chin, Ken Lee
    Mazidi, Mohsen
    Zomer, Ella
    Bell, J. Simon
    Magliano, Dianna J.
    Liew, Danny
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2019, 158
  • [30] Medication persistence with and adherence to dipeptidyl peptidase-4 inhibitors among patients with diabetes type II in Slovenia
    Jazbar, Janja
    Prelesnik, Sara
    Vodopivec, Klemen
    Makovec, Urska Nabergoj
    Locatelli, Igor
    Kos, Mitja
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2022, 44 (03) : 800 - 801
12345